EDITORIAL-DETAILS (JPDM)
Liqin Zhao
Assistant Professor
University of Kansas School of Pharmacy
USA
Biography
Dr. Zhao received her PhD in Pharmaceutical Sciences from Shenyang Pharmaceutical University in China in 1999 and continued her postdoctoral research in neuroscience at the Beijing Institute of Pharmacology and Toxicology. Dr. Zhao joined the University of Southern California in 2002 and most recently served as a Research Associate Professor of Pharmacology & Pharmaceutical Sciences and Director of Core Facilities & Services in the School of Pharmacy. In August 2013, Dr. Zhao joined the faculty as a Tenure-Track Assistant Professor in the Department of Pharmacology and Toxicology at the University of Kansas School of Pharmacy. Dr. Zhao has served as a principal investigator or co-investigator on a number of research projects funded by the Alzheimer’s Association and National Institute on Aging. In recognition of her work on estrogen receptor (ER) beta and achievement in bench to bedside translational development of an ERbeta-selective therapy (two patents granted and one pending) that is currently under evaluation in a phase I/IIa clinical trial, Dr. Zhao was chosen as one of five researchers profiled in the Alzheimer’s Association’s annual report: The Year in Alzheimer Science 2010. Moreover, Dr. Zhao is recognized by the Association under: Spotlight on Researchers Dedicated to Alzheimer’s
Research Interest
Research, focusing on neurobiology of aging and neurodegeneration (with an emphasis on Alzheimer’s disease; AD), aims: • At the basic level, to understand the neurobiological effects of sex hormones and the molecular basis underlying sex differences in the risk of developing AD. Some particular areas of interest include: menopause/perimenopause, estrogen receptor beta, insulin/IGF signaling, insulindegrading enzyme, energy metabolism, apolipoproteins, and gene expression and regulation. • At the translational level, to advance basic scientific findings into therapeutic development for prevention and early intervention of pathological brain aging and neurodegeneration. Some particular areas of focus include: non-hormonal alternative therapies, estrogen receptor beta modulators, phytochemicals, and lifestyles in modulation of aging health.